Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2, Single-arm, Open-label, Multi-center Study of MP0250 in Combination With Osimertinib in Patients With EGFR-mutated Non-squamous Non-small Cell Lung Cancer (NSCLC) Pretreated With Osimertinib

X
Trial Profile

A Phase 1b/2, Single-arm, Open-label, Multi-center Study of MP0250 in Combination With Osimertinib in Patients With EGFR-mutated Non-squamous Non-small Cell Lung Cancer (NSCLC) Pretreated With Osimertinib

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 27 Mar 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MP 0250 (Primary) ; Osimertinib
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Molecular Partners AG
  • Most Recent Events

    • 27 May 2020 Status changed from suspended to discontinued.
    • 09 May 2019 According to a Molecular Partners AG media release, the company has suspended enrollment of new patients in this trial following observation of adverse events in the kidney in this study leading to a partial clinical hold. The company is working with the FDA to lift the hold by examining the relationship between MP0250 treatment and risk of kidney injury.
    • 09 May 2019 Status changed from active, no longer recruiting to suspended, according to a Molecular Partners AG media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top